Felixvet Introduces Maropitant Citrate Chewable Tablets for the Prevention of Vomiting and Motion Sickness in Dogs

Kansas City, Mo. — June 30, 2026 — Felixvet Inc. today announced the commercial availability of Maropitant Citrate Chewable Tablets, an FDA-approved antiemetic indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. Approved by the U.S. Food and Drug Administration on January 12, 2026, under ANADA 200-833, the product expands Felixvet’s growing portfolio of companion animal pharmaceuticals and provides veterinarians with an important treatment option for one of the most common conditions seen in veterinary practice.

Product Details

“We’re excited to bring Maropitant Citrate Chewable Tablets to the veterinary market and expand access to a therapy veterinarians rely on every day,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “Vomiting and motion sickness are common challenges for dogs and their owners, and this approval provides veterinarians with an FDA-approved chewable formulation that offers convenience, dosing flexibility, and a trusted treatment option.”

Maropitant Citrate Chewable Tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

The product is therapeutically equivalent to the pioneer drug and provides the same safety and efficacy profile. Maropitant Citrate Chewable Tablets are available in four strengths:

• 16 mg 
• 24 mg 
• 60 mg 
• 160 mg 

Each tablet is scored to support accurate dosing and is available in both bottle and blister pack presentations. 

“At Felixvet, we’re focused on bringing high-quality products to market that support the everyday needs of veterinarians and pet owners,” added Lauren Landolph. “The addition of Maropitant Citrate Chewable Tablets reflects our commitment to expanding access to important therapies across companion animal medicine.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across a broad range of therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com